{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:54:47Z","timestamp":1769576087629,"version":"3.49.0"},"reference-count":55,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,9,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To test the hypothesis that early postnatal dexamethasone will reduce the incidence of death or chronic lung disease (CLD) in ventilated extremely low birth weight premature infants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design.<\/jats:title><jats:p>Multicenter randomized double-blinded controlled clinical trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting.<\/jats:title><jats:p>A total of 42 neonatal intensive care units in the Vermont Oxford Network.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants.<\/jats:title><jats:p>Infants weighing 501 to 1000 g were eligible for enrollment at 12 hours of age if they needed assisted ventilation, had received surfactant replacement therapy, were physiologically stable, had no obvious life-threatening congenital anomaly, and had blood cultures obtained and antibiotic therapy initiated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention.<\/jats:title><jats:p>Infants were randomly assigned to dexamethasone or saline placebo. Intravenous dexamethasone was administered for 12 days according to the following dosing schedule: 0.5 mg\/kg\/d for 3 days, 0.25 mg\/kg\/d for 3 days, 0.10 mg\/kg\/d for 3 days, 0.05 mg\/kg\/d for 3 days. Infants in either group could receive treatment with selective late postnatal steroids beginning on day 14 of life if they were on assisted ventilation with supplemental oxygen greater than 30%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome Measurements.<\/jats:title><jats:p>The primary outcome measure was CLD or death at 36 weeks postmenstrual age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>The study was stopped before completion of sample size goals because of concern about serious side effects in the early steroid treatment group. A total of 542 infants were enrolled (early treatment N = 273, control N = 269). The 2 groups had similar demographic characteristics. No differences were noted in the primary outcome of CLD or death at 36 weeks postmenstrual age (early treatment 50% vs control: 53%, relative risk: 0.93; 95% confidence interval [CI]: 0.79\u20131.09). Fewer infants who received early steroid treatment had a patent ductus arteriosus (relative risk: 0.78; 95% CI: 0.63\u20130.96), and fewer infants in the early steroid group received indomethacin therapy (relative risk: 0.74; 95% CI: 0.64\u20130.86) or late steroid treatment (relative risk: 0.69; 95% CI: 0.58\u20130.81). However, more infants who received early steroid treatment had complications associated with therapy including an increase in hyperglycemia (relative risk: 1.29; 95% CI: 1.13\u20131.46) and an increase in the use of insulin therapy (relative risk: 1.62; 95% CI: 1.36\u20131.94). A trend toward increased gastrointestinal hemorrhage (relative risk: 1.55; 95% CI: 0.92\u20132.61), gastrointestinal perforation (relative risk: 1.53; 95% CI: 0.89\u20132.61), and an increased systolic blood pressure (relative risk: 1.34; 95% CI: 0.97\u20131.85) was noted. In infants receiving cranial ultrasound examinations, a marginal increase in periventricular leukomalacia was noted in the early steroid treatment group (relative risk: 2.23; 95% CI: 0.99\u20135.04). Infants who received early steroid therapy had fewer days in supplemental oxygen but experienced poor weight gain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>A 12-day course of early postnatal steroid therapy given to extremely low birth weight infants did not decrease the risk of CLD or death at 36 weeks postmenstrual age and was associated with an increased risk of complications and poor weight gain.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.108.3.741","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:55:51Z","timestamp":1092441351000},"page":"741-748","source":"Crossref","is-referenced-by-count":89,"title":["Early Postnatal Dexamethasone Therapy for the Prevention of Chronic Lung Disease"],"prefix":"10.1542","volume":"108","author":[{"name":"The Vermont Oxford Network Steroid Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2001,9,1]]},"reference":[{"key":"2021121010025461400_B1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1542\/peds.92.2.191","article-title":"Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. The Members of the National Institute of Child Health and Human Development Neonatal Research Network [see comments].","volume":"92","author":"Horbar","year":"1993","journal-title":"Pediatrics."},{"key":"2021121010025461400_B2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1542\/peds.90.5.663","article-title":"Improved survival accounts for most, but not all, of the increase in bronchopulmonary dysplasia.","volume":"90","author":"Parker","year":"1992","journal-title":"Pediatrics."},{"key":"2021121010025461400_B3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-3476(81)80774-3","article-title":"Growth and development in children recovering from bronchopulmonary dysplasia.","volume":"98","author":"Markestad","year":"1981","journal-title":"J Pediatr."},{"key":"2021121010025461400_B4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/archpedi.1982.03970410061015","article-title":"Infants with bronchopulmonary dysplasia. Growth pattern and neurologic and developmental outcome.","volume":"136","author":"Vohr","year":"1982","journal-title":"Am J Dis Child."},{"key":"2021121010025461400_B5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1469-8749.1991.tb14946.x","article-title":"Neurodevelopmental and medical status of low-birthweight survivors of bronchopulmonary dysplasia at 10 to 12 years of age.","volume":"33","author":"Vohr","year":"1991","journal-title":"Dev Med Child Neurol."},{"key":"2021121010025461400_B6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/000992289303200702","article-title":"Financial and emotional cost of bronchopulmonary dysplasia.","volume":"32","author":"McAleese","year":"1993","journal-title":"Clin Pediatr."},{"key":"2021121010025461400_B7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0045-9380(94)90033-7","article-title":"Advances and issues in bronchopulmonary dysplasia.","volume":"24","author":"Zimmerman","year":"1994","journal-title":"Curr Probl Pediatr."},{"key":"2021121010025461400_B8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1146\/annurev.physiol.62.1.825","article-title":"Lung development and function in preterm infants in the surfactant treatment era.","volume":"62","author":"Jobe","year":"2000","journal-title":"Annu Rev Physiol."},{"key":"2021121010025461400_B9"},{"key":"2021121010025461400_B10","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0022-3476(09)90024-5","article-title":"Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease.","volume":"122","author":"Groneck","year":"1993","journal-title":"J Pediatr."},{"key":"2021121010025461400_B11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0022-3476(88)80390-1","article-title":"Effects of dexamethasone and indomethacin on elastase, alpha 1-proteinase inhibitor, and fibronectin in bronchoalveolar lavage fluid from neonates.","volume":"113","author":"Gerdes","year":"1988","journal-title":"J Pediatr."},{"key":"2021121010025461400_B12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/thx.47.1.44","article-title":"Tumor necrosis factor in the bronchoalveolar secretions of infants with the respiratory distress syndrome and the effect of dexamethasone treatment.","volume":"47","author":"Murch","year":"1992","journal-title":"Thorax."},{"key":"2021121010025461400_B13"},{"key":"2021121010025461400_B14","first-page":"276","article-title":"Early postnatal corticosteroids for the prevention of chronic lung disease (CLD): meta-analysis of clinical trials [abstract].","volume":"37","author":"Vijayakumaran","year":"1995","journal-title":"Pediatr Res."},{"key":"2021121010025461400_B15","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM198906083202301","article-title":"A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia.","volume":"320","author":"Cummings","year":"1989","journal-title":"N Engl J Med."},{"key":"2021121010025461400_B16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0022-3476(78)80282-0","article-title":"Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm.","volume":"92","author":"Papile","year":"1978","journal-title":"J Pediatr."},{"key":"2021121010025461400_B17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1542\/peds.74.1.127","article-title":"An international classification of retinopathy of prematurity.","volume":"74","author":"Anonymous","year":"1984","journal-title":"Pediatrics."},{"key":"2021121010025461400_B18","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(83)92139-6","article-title":"Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia.","volume":"1","author":"Mammel","year":"1983","journal-title":"Lancet."},{"key":"2021121010025461400_B19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1542\/peds.75.1.106","article-title":"Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia.","volume":"75","author":"Avery","year":"1985","journal-title":"Pediatrics."},{"key":"2021121010025461400_B20","first-page":"421","article-title":"Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Collaborative Dexamethasone Trial Group.","volume":"88","author":"Anonymous","year":"1991","journal-title":"Pediatrics."},{"key":"2021121010025461400_B21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0022-3476(89)80754-1","article-title":"Dexamethasone therapy for chronic lung disease in ventilator- and oxygen-dependent infants: a controlled trial.","volume":"115","author":"Harkavy","year":"1989","journal-title":"J Pediatr."},{"key":"2021121010025461400_B22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1651-2227.1992.tb12096.x","article-title":"Randomized controlled trial of dexamethasone treatment in very-low-birth-weight infants with ventilator-dependent chronic lung disease.","volume":"81","author":"Ohlsson","year":"1992","journal-title":"Acta Paediatr."},{"key":"2021121010025461400_B23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/adc.68.5_Spec_No.566","article-title":"Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia.","volume":"68","author":"Kari","year":"1993","journal-title":"Arch Dis Child."},{"key":"2021121010025461400_B24"},{"key":"2021121010025461400_B25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ana.410020503","article-title":"The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurological hazards.","volume":"2","author":"Weichsel","year":"1977","journal-title":"Ann Neurol."},{"key":"2021121010025461400_B26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00006454-198807000-00011","article-title":"Immunosuppressive effects and infections associated with corticosteroid therapy.","volume":"7","author":"Mukwaya","year":"1988","journal-title":"Pediatr Infect Dis J."},{"key":"2021121010025461400_B27"},{"key":"2021121010025461400_B28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0022-3476(05)80446-9","article-title":"Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia.","volume":"120","author":"Werner","year":"1992","journal-title":"J Pediatr."},{"key":"2021121010025461400_B29","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1542\/peds.90.4.646","article-title":"Steroids, chronic lung disease, and retinopathy of prematurity.","volume":"90","author":"Ehrenkranz","year":"1992","journal-title":"Pediatrics."},{"key":"2021121010025461400_B30","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0022-3476(88)80398-6","article-title":"A randomized, placebo-controlled trial of effects of dexamethasone on hypothalamic-pituitary-adrenal axis in preterm infants.","volume":"113","author":"Wilson","year":"1988","journal-title":"J Pediatr."},{"key":"2021121010025461400_B31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1542\/peds.50.4.526","article-title":"A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome.","volume":"50","author":"Baden","year":"1972","journal-title":"Pediatrics."},{"key":"2021121010025461400_B32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0022-3476(05)80547-5","article-title":"Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study [see comments].","volume":"117","author":"Yeh","year":"1990","journal-title":"J Pediatr."},{"key":"2021121010025461400_B33"},{"key":"2021121010025461400_B34","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1542\/peds.98.2.204","article-title":"A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants.","volume":"98","author":"Rastogi","year":"1996","journal-title":"Pediatrics."},{"key":"2021121010025461400_B35","first-page":"38","article-title":"Does early dexamethasone prevent PDA? Abstract.","volume":"35","author":"Morales","year":"1994","journal-title":"Pediatr Res."},{"key":"2021121010025461400_B36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1203\/00006450-199407001-00022","article-title":"Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome.","volume":"36","author":"Sanders","year":"1994","journal-title":"Pediatr Res."},{"key":"2021121010025461400_B37","first-page":"1","article-title":"A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-Oxford Neonatal Network.","volume":"97","author":"Anonymous","year":"1996","journal-title":"Pediatrics."},{"key":"2021121010025461400_B38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1542\/peds.104.1.91","article-title":"A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial.","volume":"104","author":"Garland","year":"1999","journal-title":"Pediatrics."},{"key":"2021121010025461400_B39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0022-3476(99)70132-0","article-title":"A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants.","volume":"135","author":"Kopelman","year":"1999","journal-title":"J Pediatr."},{"key":"2021121010025461400_B40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/(SICI)1099-0496(199901)27:1<21::AID-PPUL5>3.0.CO;2-Y","article-title":"Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy.","volume":"27","author":"Lin","year":"1999","journal-title":"Pediatr Pulmonol."},{"key":"2021121010025461400_B41","first-page":"117","article-title":"Role of early postnatal dexamethasone in respiratory distress syndrome.","volume":"35","author":"Mukhopadhyay","year":"1998","journal-title":"Indian Pediatr."},{"key":"2021121010025461400_B42","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s001340050935","article-title":"Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants.","volume":"25","author":"Romagnoli","year":"1999","journal-title":"Intensive Care Med."},{"key":"2021121010025461400_B43","doi-asserted-by":"crossref","first-page":"F33","DOI":"10.1136\/fn.74.1.F33","article-title":"Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome.","volume":"74","author":"Shinwell","year":"1996","journal-title":"Arch Dis Child Fetal Neonatal Ed."},{"key":"2021121010025461400_B44","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1542\/peds.105.3.542","article-title":"Early dexamethasone\u2014attempting to prevent chronic lung disease.","volume":"105","author":"Sinkin","year":"2000","journal-title":"Pediatrics."},{"key":"2021121010025461400_B45","first-page":"434","article-title":"Serious complications in a randomized trial or early stress dose dexamethasone (DEX) in extremely low birth weight (ELBW) infants [abstract].","volume":"47","author":"Stark","year":"2000","journal-title":"Pediatr Res."},{"key":"2021121010025461400_B46","doi-asserted-by":"crossref","first-page":"F185","DOI":"10.1136\/fn.77.3.F185","article-title":"Open randomized controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants.","volume":"77","author":"Subhedar","year":"1997","journal-title":"Arch Dis Child Fetal Neonatal Ed."},{"key":"2021121010025461400_B47","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1651-2227.1996.tb14132.x","article-title":"Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants.","volume":"85","author":"Suske","year":"1996","journal-title":"Acta Paediatr."},{"key":"2021121010025461400_B48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-3476(98)70483-4","article-title":"The effect of early dexamethasone administration on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome.","volume":"132","author":"Tapia","year":"1998","journal-title":"J Pediatr."},{"key":"2021121010025461400_B49","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/thx.51.9.907","article-title":"Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome.","volume":"51","author":"Wang","year":"1996","journal-title":"Thorax."},{"key":"2021121010025461400_B50","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1542\/peds.104.6.1258","article-title":"Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants.","volume":"104","author":"Watterberg","year":"1999","journal-title":"Pediatrics."},{"key":"2021121010025461400_B51"},{"key":"2021121010025461400_B52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00000542-199902000-00028","article-title":"Dexamethasone changes brain monoamine metabolism and aggravates ischemic neuronal damage in rats.","volume":"90","author":"Tsubota","year":"1999","journal-title":"Anesthesiology."},{"key":"2021121010025461400_B53"},{"key":"2021121010025461400_B54","first-page":"257","article-title":"Assessing bronchopulmonary dysplasia risk within 24 hours of surfactant therapy for an early intervention trial.","volume":"37","author":"Garland","year":"1995","journal-title":"Pediatr Res."},{"key":"2021121010025461400_B55","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJM199904013401304","article-title":"Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia.","volume":"340","author":"Cole","year":"1999","journal-title":"N Engl J Med."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/3\/741\/888932\/741.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/3\/741\/888932\/741.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:32:14Z","timestamp":1682746334000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/108\/3\/741\/66611\/Early-Postnatal-Dexamethasone-Therapy-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9,1]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2001,9,1]]},"published-print":{"date-parts":[[2001,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.108.3.741","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2001,9,1]]}}}